Ceapro Inc. Reports 2023 Third Quarter and Nine-Month : vima

– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology...

Related Keywords

Austria , Canada , Montreal , Quebec , Vienna , Wien , China , Canadian , Austrian , Beta Glucan , Gilles Gagnon , Jenene Thomas , Prozesstechnologie Gmb , Corporate Communications Advisor , Expanded Technology , Corealis Inc , Clinical Development , Manufacturing Services , Montreal Heart Institute , Energy Booster , Mcmaster University , Nasdaq , Pipeline Development , Ceapro Inc , Technology Avenanthramides , Angiogenesis Foundation , Clinical Trial , Healing Tissue Regeneration , Third Quarter , Nine Month Period Ended September , Interim Consolidated Balance Sheets , Interim Consolidated Statements , Cash Flows , Months Ended September , Corporate Communications , Tsx Venture Exchange Czo ,